Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41st Annual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco.  Tony J. Hunt, President and Chief Executive Officer, will present on Tuesday, January 10, 2023, at 2:15 p.m. PST. A live webcast of the presentation will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences. The Stifel 2022 Healthcare Conference being held November 15-16 in New York. Jon K. Snodgres, Chief Financial Officer, will participate in an analyst-led discussion on Wednesday, November 16, at 2:25 p.m. EST. Stephens’ Annual Investment Conference being held November 15-17 in Nashville. Mr. Snodgres will participate in an analyst-led discussion on Thursday, November 17, at 2:00 p.m. EST.
A live webcast of the discussions will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing
external link icon
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.
Stifel’s 2021 Virtual Healthcare Conference being held November 15-17. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, November 17, at 8:00 a.m. EST. Stephens Annual Investment Conference being held December 1-3. Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Friday, December 3, at 11:00 a.m. EST.
A live webcast of the discussions will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative
external link icon
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.
The availability of this COVID-19 affinity resin is the result of an accelerated program to provide COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these critical vaccines. Working closely with Navigo Proteins on the ligand development and partnering with Purolite Life Sciences on Praesto ® agarose bead technology, the resulting product meets all the
external link icon
Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 37 th Annual J.P. Morgan Healthcare conference being held January 7-10 at the Westin St. Francis in San Francisco.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Tuesday, January 8, at 5:30 p.m. PST.

A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing-focused company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity
external link icon
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact™ A,  which will be commercialized by Purolite Life Sciences using their novel Praesto® agarose jetting base bead technology. Repligen is a longtime market leader in Protein A, with two facilities that produce the majority of the global Protein A ligand demand to biopharmaceutical customers worldwide. NGL-Impact™ A was developed as part of Repligen’s collaboration with Navigo Proteins GmbH. This new ligand has outstanding performance attributes when immobilized on jetted agarose bead technology, with ultra-high binding capacities and excellent alkaline stability. These attributes are important in providing improved monoclonal antibody capture to handle increased upstream product titres, and in
external link icon
Repligen To Present at 36th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing-focused company delivering technology innovation to improve biologic drug manufacturing flexibility and efficiency, today announced that the Company will be presenting at the 36 th Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2018 in San Francisco. Tony J. Hunt, President and CEO of Repligen, will present a company overview on Tuesday, January 9 at 4:00 p.m. PT. 
A live webcast of the event will be accessible through the Investor Relations section of Repligen’s website. This webcast will be archived for a period of time following the live event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein
external link icon
Repligen to Present at 35th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 35 th Annual J.P. Morgan Healthcare conference being held January 9-12 at the Westin St. Francis in San Francisco.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Thursday, January 12, at 11:00 a.m. PST.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the process of manufacturing biologic drugs. Our bioprocessing products are sold to major life sciences companies,
external link icon
Repligen to Present at Jefferies 2016 Healthcare Conference
WALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 8:00 a.m. ET on Wednesday, June 8 in New York. A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation  Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of
external link icon
Repligen Announces Extension of Long Term Supply Agreement for Protein A
WALTHAM, Mass., Feb. 24, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it has extended through 2019 a key long-term supply agreement with GE Healthcare for the manufacture of Protein A ligands at the Company’s facility in Lund, Sweden. In extending this agreement, the Company aligned important manufacturing and supply terms with its existing GE Healthcare long-term supply agreement, which runs through 2021, for production out of the Company’s Waltham, MA facility. The combined agreements maintain Repligen as the main strategic supplier of recombinant and native forms of Protein A ligands to GE Healthcare. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “This agreement ensures the supply of high quality Protein A ligands to GE Healthcare. Our longtime collaboration is supported by Repligen’s business continuity plans, quality systems and access to our research and development team. We are proud of our Protein A manufacturing
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support